{"id":"absence-epilepsy-medications","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation or drowsiness"},{"rate":null,"effect":"Ataxia or dizziness"},{"rate":null,"effect":"Behavioral changes"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL552659","moleculeType":"Small molecule","molecularWeight":"477.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs typically act on ion channels or neurotransmitter systems to suppress the synchronized thalamic-cortical oscillations that underlie absence seizures. Common mechanisms include enhancement of GABAergic inhibition, modulation of T-type calcium channels, or effects on sodium channels. The goal is to prevent the 3 Hz spike-and-wave discharges seen on EEG during absence seizures.","oneSentence":"Absence epilepsy medications work by reducing abnormal electrical activity in the brain that causes brief lapses in consciousness characteristic of absence seizures.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:35.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Absence epilepsy (childhood absence epilepsy, juvenile absence epilepsy)"}]},"trialDetails":[{"nctId":"NCT06315322","phase":"PHASE3","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-07-10","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":120},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT05109234","phase":"PHASE3","title":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-03-30","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":84},{"nctId":"NCT06769659","phase":"PHASE2","title":"A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures","status":"RECRUITING","sponsor":"NeuroPro Therapeutics, Inc.","startDate":"2025-03-11","conditions":"Epilepsy, Generalized, Epilepsy, Absence","enrollment":10},{"nctId":"NCT04274179","phase":"PHASE3","title":"Ketogenic Diet for New-Onset Absence Epilepsy","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-08-10","conditions":"Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence","enrollment":40},{"nctId":"NCT04924933","phase":"NA","title":"Evaluation of Memory and Forgetting in Patients With Epilepsy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-01-26","conditions":"Epilepsy","enrollment":83},{"nctId":"NCT06263920","phase":"","title":"Neurofrailty: A Study of Late-onset Epilepsy and Its Associations","status":"RECRUITING","sponsor":"Lancashire Teaching Hospitals NHS Foundation Trust","startDate":"2022-05-05","conditions":"Late Onset Epilepsy, Stroke, Dementia","enrollment":360},{"nctId":"NCT04552756","phase":"NA","title":"Seizures During Radiotherapy for High-grade Gliomas","status":"TERMINATED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2021-03-01","conditions":"High-grade Glioma","enrollment":23},{"nctId":"NCT03336242","phase":"PHASE2","title":"Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2017-12-29","conditions":"Childhood Absence Epilepsy","enrollment":20},{"nctId":"NCT04899050","phase":"PHASE4","title":"Epidiolex in Typical Absence Seizures","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2021-07-30","conditions":"Study the Efficacy of Epidiolex for Typical Absence Seizures","enrollment":14},{"nctId":"NCT04650204","phase":"PHASE4","title":"Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-12-04","conditions":"Intractable Epilepsy, Malignant Glioma, Seizure Disorder","enrollment":4},{"nctId":"NCT03355300","phase":"PHASE2","title":"Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2018-02-20","conditions":"Childhood Absence Epilepsy","enrollment":11},{"nctId":"NCT03595475","phase":"","title":"Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2017-10-01","conditions":"REM Sleep Behavior Disorder","enrollment":408},{"nctId":"NCT03059381","phase":"","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-08-01","conditions":"Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures","enrollment":519},{"nctId":"NCT03059329","phase":"","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-08-01","conditions":"Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures","enrollment":3809},{"nctId":"NCT00088452","phase":"PHASE3","title":"Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-07","conditions":"Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy","enrollment":453},{"nctId":"NCT02767037","phase":"NA","title":"SudoScan as a Biomarker of Parkinson's Disease","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-06","conditions":"Parkinson's Disease","enrollment":150},{"nctId":"NCT02766595","phase":"NA","title":"Does Body Positioning Affect the Yield of Hyperventilation in Routine Pediatric Electroencephalography - EEG Studies?","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2016-06","conditions":"Epilepsy, Absence","enrollment":50},{"nctId":"NCT01178437","phase":"NA","title":"Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy","status":"COMPLETED","sponsor":"cerbomed GmbH","startDate":"2009-08","conditions":"Epilepsy","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ethosuximide, valproate or lamotrigine"],"phase":"phase_3","status":"active","brandName":"Absence epilepsy medications","genericName":"Absence epilepsy medications","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Absence epilepsy medications work by reducing abnormal electrical activity in the brain that causes brief lapses in consciousness characteristic of absence seizures. Used for Absence epilepsy (childhood absence epilepsy, juvenile absence epilepsy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}